Develops experimental medicines that stabilize a cystic fibrosis-related protein and other medicines designed to improve its function, for people with cystic fibrosis.
10-K for FY2025, filed Mar 2, 2026We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”)…View ↗
We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. The…View ↗
Our proprietary portfolio is anchored by our NBD1 stabilizers and our complementary modulators. Our portfolio includes:View ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
−$32.4MView ↗
Competes with Vertex and Fair Therapeutics
10-K for FY2025, filed Mar 2, 2026In particular, we expect to compete with Vertex, which has multiple approved products, as well as additional product candidates in…View ↗
Loading...